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ABSTRACT
Objective: For 3,670 stroke patients from the United Kingdom, United States, Australia, Belgium, and
Italy, we performed a genome-wide meta-analysis of white matter hyperintensity volumes (WMHV) on
data imputed to the 1000 Genomes reference dataset to provide insights into disease mechanisms.
Methods: We first sought to identify genetic associations with white matter hyperintensities in a
stroke population, and then examined whether genetic loci previously linked to WMHV in community
populations are also associated in stroke patients. Having established that genetic associations are
shared between the 2 populations, we performed a meta-analysis testing which associations with
WMHV in stroke-free populations are associated overall when combined with stroke populations.
Results: There were no associations at genome-wide significance with WMHV in stroke patients. All
previously reported genome-wide significant associationswithWMHV in community populations shared
direction of effect in stroke patients. In a meta-analysis of the genome-wide significant and suggestive
loci (p, 53 1026) from community populations (15 single nucleotide polymorphisms in total) and from
stroke patients, 6 independent loci were associated with WMHV in both populations. Four of these are
novel associations at the genome-wide level (rs72934505 [NBEAL1], p 5 2.2 3 1028; rs941898
[EVL], p5 4.03 1028; rs962888 [C1QL1], p5 1.13 1028; rs9515201 [COL4A2], p5 6.93 1029).
Conclusions: Genetic associations withWMHV are shared in otherwise healthy individuals and pa-
tients with stroke, indicating common genetic susceptibility in cerebral small vessel disease.
Neurology® 2016;86:146–153
GLOSSARY
FLAIR 5 fluid-attenuated inversion recovery; ROI 5 region of interest; SNP 5 single nucleotide polymorphism; TICV 5 total
intracranial volume;WMH 5 white matter hyperintensities;WMHV 5 white matter hyperintensity volume;WTCCC2 5Well-
come Trust Case Control Consortium–2.
White matter hyperintensities (WMH) on T2-weighted MRI are associated with increasing age
and cardiovascular risk factors, particularly hypertension, and are predictive of both stroke and
dementia in prospective community populations.1 Severe confluent WMH are often found in
patients presenting with stroke, and are more common in patients with the small vessel stroke
subtype.2 Furthermore, in these patients, WMH burden is linked to poor clinical outcomes after
stroke.3,4 Understanding disease mechanisms that contribute toWMH could lead to advances in
prevention, treatment, and rehabilitation of disability related to vascular cognitive impairment,
age-related functional decline, and stroke.
Twin and family history studies suggest a significant genetic component to WMH. Herita-
bility estimates range from 55% to 80%,5–8 suggesting that a moderate to large proportion of the
disease risk can be attributed to genetic effects. The heritability attributed to common single
nucleotide polymorphisms (SNPs) has been estimated to be between 13% and 45%.9 Previous
genome-wide analyses have focused on the genetic influence on WMH in community popu-
lations,10,11 and a recent meta-analysis identified 8 regions associated with the disease.12 One
*These authors contributed equally to this work.
Authors’ affiliations are listed at the end of the article.
Coinvestigators are listed on the Neurology® Web site at Neurology.org.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was paid by Wellcome Trust.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited.
146 © 2015 American Academy of Neurology
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
might expect genetic risk factors for WMH in
community populations to be similar to those
that confer increased risk of WMH in stroke
patients. However, the underlying pathology
of WMH is heterogeneous, with small punc-
tate lesions being associated with mixed
causes, whereas more confluent areas often
seen in stroke patients correspond primarily
to small vessel disease.13 Therefore, it is
unclear whether the lesions underlying
WMH in the general population are patholog-
ically distinct from the confluent lesions fre-
quently observed in patients with stroke.
In this analysis, we investigated the role of
the genetic contribution to WMH volumes
(WMHV) in patients with ischemic stroke.
We initially performed a genome-wide meta-
analysis of WMHV in stroke patients with
the aim of identifying novel associations. Sec-
ond, we determined whether similar genetic
factors contributed to WMHV in community
populations and stroke patients. Finally, hav-
ing established shared genetic factors in the 2
datasets, we performed a meta-analysis of the
published associations from community popu-
lations with our dataset to identify genetic as-
sociations that are in common in the 2
populations.
METHODS Study populations. Ischemic stroke populations
were enrolled through hospital-based studies between 1995 and
2013. Characteristics of the study populations are given in
table 1; full details are given in the supplementary material on
the Neurology® Web site at Neurology.org. Patients with cerebral
autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy or any other suspected monogenic cause
of stroke, vasculitis, or any other nonischemic cause of WMH
including demyelinating and mitochondrial disorders were
excluded from analyses.
Standard protocol approvals, registrations, and patient
consents. An institutional review board or regional review board
approved the use of human subjects in each of the study popula-
tions. All patients gave informed consent.
Neuroimaging analysis. MRI scans were acquired as part of
routine clinical practice for evaluation of ischemic stroke (table
e-1). Fluid-attenuated inversion recovery (FLAIR) sequences
were primarily used for WMH volumetric analysis; however, in
their absence, T2-weighted sequences were used (Wellcome
Trust Case Control Consortium–2 [WTCCC2], Oxford, and
WTCCC2, Munich, only). In all scans, to avoid confounding
by hyperintense signal due to acute stroke, WMHV was assessed
quantitatively in the hemisphere contralateral to the acute
infarction. Chronic lacunar infarcts were identified using
standard criteria as low signal on T1 or FLAIR images and
were excluded from WMHV estimates.14 Trained raters blinded
to all patient information analyzed anonymized MRI scans. All
supratentorial white matter and deep gray matter lesions were
included in WMHV with the exception of WMH
corresponding to infarcts, both lacunar and territorial.2 MRIs
with excessive movement artefact, incomplete brain coverage,
or bihemispheric infarcts (other than lacunar) were excluded.
To account for interindividual variability in head size, an esti-
mate of total intracranial volume (TICV) was derived using site-
specific volumetric methodology, as follows. MRIs from the
Massachusetts General Hospital, Ischemic Stroke Genetics Study,
and Australian Stroke Genetics Collaborative studies were analyzed
in Boston. Scans from the Siblings with Ischaemic Stroke Study
were analyzed in the same way at the University of Virginia by
the Boston-trained rater. FLAIR sequences were analyzed using
an MRIcro semiautomated method as previously described.2 Using
operator-mediated quality assurances, overlapping regions of inter-
est (ROIs) corresponding to WMH produced the final maps for
WMHV calculation. Intracranial area was derived as a validated
marker of TICV as the average of 2 midsagittal slices traced using
anatomical landmarks on T1 sequences.15
The WTCCC2, GENESIS, SGUL, Leuven, and Milan co-
horts were analyzed in London using DISPunc semiautomated
lesion drawing software.16 A seed at the lesion border was first
marked manually, and then outlined automatically based on the
signal intensity gradient. Each WMH ROI was visually inspected
and manually corrected as required. To estimate TICV, T2-
weighted and, in their absence, FLAIR sequences were analyzed
using an automated segmentation program, SIENAX,17 which
calculates the total volume of CSF and gray and white matter
volumes.
WMHV quantification agreement across the 2 main rating
centers was performed for 50 randomly selected scans; agreement
was very good (intraclass correlation coefficient 0.95, confidence
interval 0.91–0.97, n 5 50).
Phenotype definition. To calculate the phenotype used in the
genetic analysis, WMHV were doubled to obtain a whole brain
estimate. This volume was then multiplied by the ratio of TICV
(or intracranial area) to the mean TICV (or intracranial area) for
the study, thereby correcting for natural differences in head size.
The values were natural log transformed and the resulting ln
(WMHV) values were entered into a linear regression model
including age, sex, and the first 2 ancestry-informative principal
components. To ensure the phenotype was normally distributed,
the residuals from the model were then z-transformed and used
as the WMHV phenotype in the genetic analysis.
Genome-wide genotyping and imputation. Genotyping of
all cohorts was performed on commercially available arrays from
Affymetrix (Santa Clara, CA) or Illumina (San Diego, CA) (table
e-2). All cohorts performed extensive quality control steps prior to
imputation, removing SNPs showing significant departure from
Hardy-Weinberg equilibrium, high levels of missingness, or
low minor allele frequency. Individuals were removed who did
not segregate with Hapmap II European populations based on
ancestry informative principal component analysis using
EIGENSTRAT or multidimensional scaling in PLINK.18,19
Additionally, individuals showing cryptic relatedness or having
high levels of missingness or heterozygosity were excluded. All
datasets were imputed to 1000 Genomes integrated variant set
(March 2012) using IMPUTE v2.20
Genome-wide association analysis of WMHV in stroke
patients. To discover novel associations between WMHV and
each autosomal SNP, we performed linear regression of WMHV
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on genotype dosages using PLINK v1.07.19 SNPs with PLINK
INFO,0.7 or MAF,0.01 were removed from further analyses.
We used genomic inflation to evaluate inflation of test statistics in
each study group.21 Results across all study groups were combined
using a fixed-effects inverse variance weighted method using
METAL.22 To control for any excess signal that might result
from study-wise inflation of p values, we performed genomic
control correction, multiplying the standard errors from each
study by the square root of the genomic inflation factor.21
Heterogeneity was assessed using Cochran q statistic. Following
the meta-analysis, we considered only SNPs present in more than
12 study groups, and with heterogeneity p . 0.001, for analysis.
We set the significance threshold to p , 5 3 1028. We used
l1000 to evaluate inflation at the meta-analysis level.23 We had
80% power to detect a variant explaining 1.1% of the trait
variance (figure e-1).
Analysis of SNPs associated with WMH in community-
based populations. To determine whether SNPs contributing
to WMHV in community populations were associated with
WMHV in stroke patients, we evaluated each SNP reported as
being associated with WMH in healthy adults in a recent publi-
cation,12 testing if the SNP was associated with WMHV in ische-
mic stroke patients. All 17,936 individuals in the previous study
were stroke-free and nonoverlapping with the samples studied
here. We performed this analysis first for all genome-wide
associated loci from the publication, and second for loci
reported at p , 1 31025 in European populations or overall.
We set a significance threshold at p 5 0.0033, Bonferroni
correcting for the 15 SNPs analyzed. We had 80% power to
detect any associations that explain 0.4% of the trait variance.
In addition, we tested whether there was evidence overall that
genetic susceptibility factors were shared between the 2
populations. We used a binomial test to evaluate whether an
excess of the 8 genome-wide significant SNPs shared direction
of effect in community populations and stroke patients, and then
extended this to the 15 genome-wide significant loci and loci
reported at p , 1 3 1025 in European populations or overall.
Meta-analysis of stroke samples and published population-
based samples. Having established that genetic factors were
shared between community populations and stroke patients, we
evaluated the overall evidence that each of the 15 previously re-
ported SNPs (8 genome-wide significant, 7 suggestive) were
associated with WMHV in both populations. We combined
p values from the 2 sources using Stouffer z-score weighted
method with equal weights, classifying SNPs with p , 0.05 in
both populations and reaching p , 5 3 1028 overall as
significantly associated with WMH in both populations. We
were not able to perform the reciprocal analysis, testing if
suggestive associations with WMH in stroke patients were
associated with WMH in stroke-free individuals, due to
restrictions on access to the required summary level data. We
then evaluated novel genome-wide associations in available
databases to test for evidence that affects regulation of genes
(RegulomeDB)24 or directly affects gene expression (GTEx).25
Table 1 Cohort characteristics
Study group No. Mean age, y (SD) % Male % Hypertensive
Genomic inflation
l (l1000) No. SNPs
Milan 151 57 (14) 60 57 1.01 7,959,374
WTCCC2-Edinburgh 64 68 (13) 50 62 0.99 7,875,762
WTCCC2-Munich FLAIR 447 66 (12) 66 72 1.00 8,287,283
WTCCC2-Munich T2 203 67 (12) 55 67 0.99 8,194,948
WTCCC2-Oxford FLAIR 65 65 (15) 54 65 1.03 7,891,788
WTCCC2-Oxford T2 75 67 (13) 59 68 1.02 7,979,101
WTCCC2-SGUL 323 70 (14) 63 77 0.99 8,256,772
GENESIS 1 121 67 (14) 67 62 0.99 7,554,414
GENESIS 2 228 69 (15) 58 76 0.99 7,663,158
SGUL 1 70 70 (13) 61 61 0.98 7,278,977
SGUL 2 57 68 (14) 58 72 0.97 7,399,139
DNA lacunar 303 57 (9) 72 68 0.99 7,679,415
Leuven 361 66 (15) 58 59 1.01 8,741,082
MGH-Affymetrix 476 67 (14) 60 64 1.09 7,973,366
MGH-Omni 84 64 (15) 63 68 1.02 8,234,605
MGH-Illumina 228 66 (15) 64 61 1.00 8,144,043
ASGC 96 65 (13) 57 77 1.01 8,113,545
ISGS 207 68 (14) 62 61 1.01 7,985,259
SWISS 111 66 (11) 48 74 1.02 7,927,980
Overall 3,670 1.04 (1.01) 7,567,914
Abbreviations: l 5 genomic inflation level; ASGC 5 Australian Stroke Genetics Collaborative; FLAIR 5 fluid-attenuated
inversion recovery; ISGS 5 Ischemic Stroke Genetics Study; MGH 5 Massachusetts General Hospital; SGUL 5 St.
George’s University of London; SNP 5 single nucleotide polymorphism; SWISS 5 Siblings With Ischaemic Stroke Study;
WTCCC2 5 Wellcome Trust Case Control Consortium–2.
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RESULTS Study populations. Clinical characteristics
of all participating cohorts are given in table 1. In
total, 3,670 individuals of European ancestry were
included in the 19 study groups.
Genome-wide association analysis of WMHV in stroke
patients. With the exception of one study group,
genomic inflation was well-controlled (l # 1.03,
table 1). Following quality control procedures,
7,567,914 autosomal SNPs remained for analysis.
Genomic inflation was well-controlled at the meta-
analysis level (l 5 1.04, l1000 5 1.01; figure e-2).
No SNP reached the significance level (figure 1),
although a number of loci reached p , 5 3 1026.
These are detailed in table e-3, and regional plots of
these loci are provided in figure e-3. All odds ratios
reported are per 1 SD change in normally distributed
WMHV after accounting for age, sex, and ancestry-
informative principal components.
Analysis of SNPs associated with WMH in community-
based populations. Eight independent SNPs have been
associated with WMH in community populations.12
We evaluated each of these in our dataset of stroke
patients. The direction of effect of all 8 associations
was consistent with the direction in our study. This
alone is unlikely to be due to chance (p5 7.83 1023
from binomial test). For specific SNPs, no genome-
wide associations from community populations
reached our significance threshold, although all had
p # 0.24 for association with WMH in stroke
patients, and 3 loci reached a nominal significance
level (p , 0.05) in stroke patients (rs7214628
[TRIM65], p 5 0.015; rs78857879 [EFEMP1], p 5
0.0056; rs2984613 [PMF1-BGLAP], p 5 0.017).
Additionally, 10 loci were reported as suggestively
significant in the same recent publication,12 with
p, 13 1025 in Europeans or overall. Three of these
were rare (MAF# 0.02), and were not imputed with
enough accuracy to be analyzed in our dataset
(rs186314186, rs150695384, rs117126031). We
evaluated each of the 7 remaining associations in
our population. Of these, 4 passed our significance
threshold (table 2). One locus was nonsignificant and
in the opposite direction in our study (rs2883428,
p 5 0.17). In total, 14 of the 15 genome-wide and
suggestively significant loci shared direction between
community individuals and stroke patients (p 5
9.8 3 1024 from binomial test).
In addition, we searched for other publications
describing associations with any of the SNPs or genes
studied using the following search terms in PubMed:
(SNP or gene) and (white matter or leukoaraiosis
or small vessel disease). No relevant publications were
identified.
Meta-analysis of stroke samples and published population-
based samples. When combining our results in stroke
patients with the 15 previously reported associations
using Stouffer z-score meta-analysis, 6 associations
reached genome-wide significance overall and had
p , 0.05 in both studies (table 2). Four of these are
novel associations at genome-wide significance
(rs72934505 [NBEAL1], p 5 2.2 3 1028; rs941898
[EVL], p 5 4.03 1028; rs962888 [C1QL1], p 5 1.1
3 1028; rs9515201 [COL4A2], p 5 6.9 3 1029), all
of which showed good consistency across the 19
cohorts (figure e-4). The same 6 associations reached
genome-wide significance using an alternative meta-
analysis approach (Fisher method). The association
with COL4A2 (rs9515201) is in strong LD (r2 .
0.8) with SNPs previously reported to be associated
with cerebral small vessel disease, and is therefore
likely to represent the same locus.26
Figure 1 Association of genome-wide single nucleotide polymorphisms with white matter hyperintensity volume in ischemic stroke patients
by genomic position
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For each of these 4 novel associations, we queried
the RegulomeDB database and GTEx portal for evi-
dence that the SNPs affect DNA binding or expres-
sion of any mRNA molecule (figure e-5).24,25
rs962888 lies 25 Kb downstream from C1QL1; how-
ever, interrogation of GTEx portal showed that the
common allele (G, risk allele) of the SNP decreases
expression of elongation factor tu GTP binding
domain containing 2 (EFTUD2) in tibial arteries,
100 kb away (p 5 5.3 3 1026). Data from Regulo-
meDB support this observation, as the SNP overlies
DNase-seq, FAIRE-seq, and CHIP-seq peaks in
numerous tissues from ENCODE.27 Similarly, the
common allele (T, risk allele) of rs72934505 increases
expression of the nearby gene NBEAL1 in tibial arter-
ies in GTEx (p 5 2.5 3 10211), and also decreases
expression of islet cell autoantigen 1.69 kDa-Like
(ICA1L) in the thyroid (p 5 6.6 3 1026), 200 kb
away. No significant eQTLs were identified for
rs941898 or rs9515201, but both overlap numerous
CHIP-seq and DNAse-seq peaks from ENCODE,
indicating they may have a regulatory function.
DISCUSSION We report the first phase of a collabo-
rative genome-wide meta-analysis of WMHV in
stroke patients. We did not identify any associations
with WMHV in ischemic stroke patients at the
genome-wide significance level. The most likely
explanation for this is lack of power. We had 80%
power to identify a variant explaining 1.1% of the
trait variance (supplementary material), suggesting
that it is unlikely that any common variants explain
more than this proportion of the variance of WMH
in stroke patients. However, we cannot rule out the
existence of rare variants conferring a considerable
proportion of disease risk.
We found strong evidence that many of the same
genome-wide associations with WMHV in healthy
individuals influence WMHV in stroke patients. All
genome-wide significant associations with WMHV
shared direction of effect in our study and 3 reached
a nominal significance threshold. More convincing is
that of the 7 suggestive associations reported with
WMH in healthy individuals, 4 were significantly
associated with WMH in stroke patients. A meta-
analysis of these SNPs in 21,606 subjects suggests
that 4 of these loci are linked toWMH in community
populations and stroke patients at genome-wide sig-
nificance. Two of these associations influence
expression of nearby gene products (NBEAL1/ICA1L
Table 2 Association of WMH-associated SNPs from community populations in stroke patients
SNP CHR:BP Nearest gene RA OA RAF
OR (95% CI)
in stroke
patients
p Value in
stroke
patients
p Value for
Europeans in
community
populations12
Overall
p value
rs7214628 17:73,882,148 TRIM65 G A 0.20 1.08 (1.01–1.14) 0.015 2.7 3 10219 2.4 3 10215a
rs72848980 10:105,319,409 NEURL G A 0.83 1.04 (0.97–1.11) 0.25 6.3 3 1029 3.4 3 1026
rs7894407 10:105,176,179 PDCD11 T C 0.65 1.02 (0.97–1.07) 0.34 1.6 3 1029 3.8 3 1026
rs12357919 10:105,438,112 SH3PXD2A T C 0.83 1.07 (1.00–1.13) 0.068 1.9 3 1028 3.8 3 1027
rs7909791 10:105,613,178 SH3PXD2A A C 0.36 1.05 (0.99–1.09) 0.069 1.7 3 1028 3.7 3 1028
rs78857879 2:56,135,099 EFEMP1 A G 0.10 1.11 (1.03–1.21) 0.0056 2.9 3 1027 5.0 3 1028a
rs2984613 1:156,197,380 PMF1-BGLAP C T 0.66 1.06 (1.01–1.12) 0.017 1.4 3 1025 4.1 3 1026
rs11679640 2:43,141,485 HAAO C G 0.80 1.04 (0.99–1.11) 0.13 4.4 3 1028 2.3 3 1026
rs72934505 2:203,916,487 NBEAL1 T G 0.88 1.10 (1.03–1.18) 0.0076 5.4 3 1028 2.2 3 1028b
rs17148926 5:121,510,586 LOC10050584 A C 0.83 1.11 (1.04–1.18) 0.0010 1.0 3 1025 9.9 3 1028
rs941898 14:100,599,437 EVL G T 0.26 1.10 (1.05–1.16) 2.3 3 1024 1.6 3 1026 4.0 3 1028b
rs6942756 7:128,886,821 AHCYL2 G T 0.26 1.03 (0.98–1.09) 0.24 8.0 3 1027 5.0 3 1025
rs2883428 1:239,571,364 XM_0039600 G A 0.25 0.96 (0.91–1.02) 0.17 4.0 3 1027 1.6 3 1025
rs962888 17:43,059,071 C1QL1 G A 0.71 1.09 (1.03–1.15) 0.0021 2.2 3 1027 1.1 3 1028b
rs9515201 13:111,040,798 COL4A2 A C 0.32 1.09 (1.04–1.15) 7.0 3 1024 6.7 3 1027 6.9 3 1029b
Abbreviations: BP 5 base position (hg19); CHR 5 chromosome; CI 5 confidence interval; OA 5 other allele; OR 5 odds ratio; RA 5 reference allele; RAF 5
reference allele frequency; SNP 5 single nucleotide polymorphism; WMH 5 white matter hyperintensities.
The top 8 SNPs are genome-wide significant in community populations overall (including all ancestries) in a previous publication,12 while the bottom 7 are
suggestively significant in community populations. The p values reported here are for Caucasian populations only. The reported reference allele is the
effect allele in community populations.
a Associated at p , 5 3 1028 overall and with p , 0.05 in both populations.
bNovel association at genome-wide level. The overall p value gives the results of Fisher meta-analysis of the p values from community populations and
stroke patients.
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[rs72934505] and EFTUD2 [rs962888]). A genome-
wide significant association with rs9515201, located
in an intron of COL4A2, which encodes collagen 4
subunit 2, was also identified. This association is par-
ticularly interesting as rare mutations in COL4A2 and
the closely related COL4A1 protein lead to small ves-
sel disease and hemorrhagic stroke,28–30 and common
variants in close LD with this SNP (r2 . 0.8) have
been linked to sporadic small vessel disease.26
The observation that genetic risk factors for
WMH in community populations also influence
WMH in stroke patients has implications. It suggests
that the white matter changes seen on the brain MRI
scans of otherwise healthy elderly reflect a similar dis-
ease process as the more severe forms that underlie
cerebral small vessel disease in patients with stroke.
Previous studies have indicated heterogeneity in
WMH pathology: our results do not preclude this
possibility, but suggest that many of the same genetic
factors contribute to both pathologies.
Our study has several strengths. Protocols were
uniformly employed across analyses, including
imputation to the same reference build across all
study groups, using the same software. Similarly,
analyses were performed using the same software
on the same phenotype, derived in the same way.
We performed volumetric analysis of all MRI scans
to quantify WMHV, which has strengths over rating
scales, which are known to have ceiling effects.14
Inter-rater agreement between the 2 coordinating
centers was shown to be good. WMHV was quan-
tified using semiautomated volumetric protocols val-
idated for use in patients with stroke and clinical
grade MRI scans.
Our study also has limitations. Large-scale collabo-
rative GWAS such as that undertaken here necessarily
combine studies with some degree of phenotypic vari-
ability. Differences in environmental exposures, possi-
bly resulting in epigenetic modifications, may
contribute to such variability, which could alter the
results. We identified 4 novel associations at genome-
wide significance when combined with previous publi-
cations. However, we have not provided replication of
these findings and therefore further evidence will be
necessary to verify these associations with WMHV.
MRI used in the analyses were drawn from a number
of centers, with varying image quality. Therefore,
to minimize bias arising from differing image quality,
we quantified WMHV per study group and meta-
analyzed the results. This approach may limit our abil-
ity to detect associations with low frequency variants
due to small sample sizes in some study groups. The
majority of MRI scans used were from FLAIR sequen-
ces. However, where these were unavailable, we used
T2-weighted images, which are less sensitive to white
matter changes. Such differences in sensitivity may
affect quantification of WMHV across study groups,
although future studies that involve centralized volu-
metric MRI analysis pipelines, such as those currently
in development, may account for this variability. In
this analysis, we considered all subtypes of stroke
together as we were underpowered to investigate
subtype-specific influences on WMH. It is possible
that causes of WMH may differ by stroke subtype,
but larger studies with sufficient power will be required
before this issue can be addressed adequately. Similarly,
it has been hypothesized that periventricular and deep
WMH might have distinct underlying pathophysiol-
ogy. In this analysis, we considered total WMHV,
rather than treating these regions separately; our lesion
volume analysis did not differentiate into these 2 re-
gions. Further analyses should address this area.
We have shown that the age-related white matter
changes seen in otherwise healthy populations share
genetic susceptibility with the extensive lesions that
underlie cerebral small vessel disease. We report 6
independent loci that are associated with WMHV
in healthy individuals as well as stroke patients, 4 of
which are novel associations at the genome-wide level.
Our results suggest that a full genome-wide meta-
analysis of available cohorts of WMH in ischemic
stroke patients and community populations is likely
to uncover further associations.
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